I haven't been consulted more recently.
My understanding is that many of the issues that Ingrid Sketris has just raised in terms of needing to put many more resources into post-market surveillance and to ensure that there is a less piecemeal process in place in terms of supporting better quality use of medicines and better quality prescribing is something you'd expect out of a national pharmaceutical strategy. So I can say what I would hope would be in there.
I don't know if you have a....